Ally Financial Inc. Invests $4.09 Million in Stryker Corporation $SYK

Ally Financial Inc. purchased a new stake in Stryker Corporation (NYSE:SYK - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,000 shares of the medical technology company's stock, valued at approximately $4,093,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Gables Capital Management Inc. purchased a new stake in Stryker in the 2nd quarter valued at $25,000. Kilter Group LLC acquired a new stake in shares of Stryker in the 2nd quarter worth $25,000. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker during the 4th quarter worth $26,000. Sankala Group LLC purchased a new position in shares of Stryker during the 4th quarter worth $26,000. Finally, Compass Financial Management LLC acquired a new position in shares of Stryker during the 2nd quarter valued at about $27,000. Institutional investors and hedge funds own 77.09% of the company's stock.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Price Performance

SYK opened at $329.86 on Monday. The stock's 50-day moving average price is $326.99 and its 200 day moving average price is $332.39. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The firm has a market cap of $126.52 billion, a price-to-earnings ratio of 34.18, a PEG ratio of 2.10 and a beta of 0.76.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker's revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Insiders Place Their Bets

In related news, VP Robert S. Fletcher sold 4,544 shares of the business's stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company's stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the company's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 665,370 shares of company stock worth $216,238,501 over the last 90 days. Corporate insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on SYK. Truist Financial increased their price objective on Stryker from $330.00 to $340.00 and gave the stock a "hold" rating in a research report on Friday, July 31st. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research report on Friday, May 1st. Argus set a $370.00 price objective on shares of Stryker in a report on Thursday, July 9th. Piper Sandler decreased their target price on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. Finally, Citigroup reaffirmed a "buy" rating on shares of Stryker in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source